# Ipsen account plan

> Ipsen is a Paris-based biopharmaceutical group in Oncology, Rare Disease and Neuroscience, with FY2025 sales of €3,675.9m and 5,535 employees.

## At a glance

Ipsen is a Paris-based global biopharmaceutical group focused on Specialty Care in Oncology, Rare Disease and Neuroscience, selling 9 drugs registered in over 100 countries with a direct commercial presence in 38 countries. Its main medicines are Somatuline, Cabometyx, Decapeptyl, Dysport, Iqirvo and Bylvay, marketed to specialists such as endocrinologists, oncologists and neurologists. FY2025 total sales were €3,675.9m (+10.9% at constant exchange rates), core operating income €1,294.1m (35.2% margin) and IFRS net profit €444.5m. It had 5,535 employees in 42 countries. Ipsen is publicly traded and family controlled, with Highrock and Beech Tree each holding 26.03% of the share capital at 31 December 2025.

## Business units

- **Oncology** (69.2% of FY2025 sales (€2,545.0m)): Somatuline for neuroendocrine tumors and acromegaly, Cabometyx (licensed from Exelixis), Decapeptyl (with Debiopharm), Onivyde and the new Ojemda. Sales grew 4.1% at CER in 2025 and 15.6% at CER in H1 2026, helped by generic lanreotide challenges; Tazverik was withdrawn in March 2026.
- **Neuroscience** (20.3% of FY2025 sales (€746.6m)): Dysport botulinum toxin for spasticity, cervical dystonia and, with partner Galderma, aesthetics, marketed in 88 countries. Sales grew 9.7% at CER in 2025 and 16.6% in H1 2026; Olivia Brown leads Neurotoxins as EVP, Global Head of Neurotoxins.
- **Rare Disease** (10.5% of FY2025 sales (€384.3m)): Iqirvo for primary biliary cholangitis, Bylvay for PFIC and Alagille syndrome, and Sohonos for FOP. Sales rose 96.5% reported in 2025 and 108.0% at CER in H1 2026, driven by Iqirvo uptake in the U.S. and European launches.

## Strategic priorities

- **Grow the portfolio beyond Somatuline**: Accelerate key medicines such as Iqirvo, Bylvay, Cabometyx and Dysport; the portfolio excluding Somatuline grew 14.2% in 2025 and 24.8% in H1 2026.
- **External innovation**: Build the pipeline mainly by sourcing assets externally in oncology, hematology and rare disease, with more than EUR 2 billion of pro forma firepower remaining after the Kartos and Memo deals.
- **Dysport in migraine launch**: After positive Phase III results in episodic and chronic migraine, submissions are planned in H2 2026 and a launch expected in H2 2027, with DTC advertising and a significantly expanded field force.
- **Expand Iqirvo**: The PBC peak sales estimate was raised to EUR 1 billion after ELSPIRE, and a Phase III in primary sclerosing cholangitis targets a population of 40,000 prevalent patients.
- **Next-generation toxins**: Develop corabotase, a first-in-class recombinant neuroinhibitor, with aesthetic proof-of-concept data later in 2026, therapeutic data in two indications in 2027 and a first aesthetic Phase III readout in 2028.
- **Margin and 2030 ambition**: Ipsen is "highly confident" of beating its 2023-2027 targets of at least 7% average annual sales growth and a 2027 core operating margin of at least 32%, and announced an enhanced ambition towards 2030 with a renewed strategy deployed in 2026.

## Latest results

In H1 2026 total sales reached €2,190.2m, up 20.4% reported and 23.5% at constant exchange rates, with Oncology +15.6%, Rare Disease +108.0% and Neuroscience +16.6% at CER. Core operating income rose 28.8% to €844.9m, a core operating margin of 38.6%, and IFRS net profit was €402.6m (+20.0%). Free cash flow was €651.7m and net cash €1,004.9m at 30 June. FY2026 guidance was raised to sales growth greater than 20.0% at CER and a core operating margin greater than 37.0%, including dilution from the Memo and Kartos acquisitions. For 2027, management expects sales growth to continue but margin to be impacted by acquired R&D and the Dysport migraine launch.

## Investments and deals

- **Kartos Therapeutics**: Agreement to acquire Kartos (navtemadlin, Phase III in myelofibrosis) for $450m upfront plus up to $1.3bn in milestones, closing anticipated by end of Q3 2026.
- **Memo Therapeutics AG**: Acquired in July 2026 for €200m upfront, adding potravitug, a Phase II antibody against BK polyomavirus in kidney transplant recipients.
- **ImCheck Therapeutics**: Acquired for €350 million upfront plus milestones, closed 15 December 2025, adding ICT01 for first-line acute myeloid leukemia.
- **Licensing and pre-clinical deals**: An ex-China licence for the SIM0613 ADC in December 2025 and seven pre-clinical assets added since January 2024, including three antibody-drug conjugates and three T cell engagers.
- **Manufacturing and financing**: €66.9m manufacturing investment in 2025 with the Wrexham (UK) toxin facility being expanded; a €500 million 3.875% bond due 2032 and a €1,500m revolving credit facility were put in place in 2025.

## Challenges and risks

- **Somatuline generics**: Somatuline, the largest product at €1,135.4m in 2025, faces generic lanreotide entry, including an Amneal launch now expected more in Q4 2026.
- **Product concentration and competition**: A few products make up the majority of sales; Dysport competes with Botox, Xeomin and other toxins, and Onivyde faces a new second-line competitor expected around September 2026.
- **R&D failures and withdrawals**: Impairments of €257.6m after tax in 2025 (Tazverik and fidrisertib), Tazverik withdrawn in March 2026 after safety signals, and Bylvay's BOLD Phase III in biliary atresia failed.
- **U.S. pricing and tariffs**: Market access and price pressure, and protectionist measures, tariffs and price-setting in the United States, are rated High risks.
- **Deal integration and IT**: Licensing, acquisition and integration of deals, and IT systems and cyberattacks, are also among the risks rated High.

## What leadership says

> "Our excellent first-half performance demonstrates the strength of Ipsen's strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate," — David Loew, Chief Executive Officer, H1 2026 results press release, 30 July 2026

> "Ipsen is delivering today accelerating growth from key medicines and expanding the pipeline to generate sustainable growth beyond 2027 with several potential blockbusters to come." — David Loew, Chief Executive Officer, H1 2026 results conference call, 30 July 2026

> "This will have a significant impact on the profitability." — Aymeric Le Chatelier, Chief Financial Officer, On 2027 margin, H1 2026 results conference call, 30 July 2026

> "We look forward to another year of accelerated growth as we continue on our transformation." — David Loew, Chief Executive Officer, Full year 2025 results conference call, 12 February 2026


## Where a supplier can help

- **Launch readiness for Dysport in migraine**: The H2 2027 migraine launch with DTC advertising and a significantly expanded field force needs field force recruitment, medical affairs, market access and campaign support.
- **Clinical operations for acquired assets**: Running Kartos's POIESIS Phase III with more than 600 patients across 250 sites and Memo's pivotal trial creates demand for CRO, site management and clinical data services.
- **Toxin manufacturing capacity**: The Wrexham toxin facility expansion and reliance on external CMO partners point to suppliers of manufacturing equipment, CMO capacity and quality services.
- **Business development diligence**: The external innovation model and remaining firepower make scientific due diligence, asset scouting and integration services relevant.
- **Cybersecurity and U.S. pricing analytics**: IT and cyberattack risk and U.S. pricing pressure, both rated High, open room for security, gross-to-net and contracting analytics providers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Ipsen 2025 Universal Registration Document](https://www.ipsen.com/wp-content/uploads/2026/04/IPSEN-UNIVERSAL-REGISTRATION-DOCUMENT-2025-ENGLISH.pdf)

Annual report · 2026-04-01

- Ipsen is a Paris-based global biopharmaceutical group focused on Specialty Care in three therapeutic areas, Oncology, Rare Disease and Neuroscience; it sells 9 drugs registered in over 100 countries, with a direct commercial presence in 38 countries and 5,535 employees in 42 countries.
- FY2025 total sales €3,675.9m, up 8.1% as reported and 10.9% at constant exchange rates; core operating income €1,294.1m (+16.7%), core operating margin 35.2% (+2.6 points); IFRS consolidated net profit €444.5m (+28.0%).
- Sales mix: Oncology 69.2% (€2,545.0m, +4.1% CER), Neuroscience 20.3% (€746.6m, +9.7%), Rare Disease 10.5% (€384.3m, +96.5% reported); Europe 39.7%, North America 35.1%, Rest of the World 25.2%.
- Somatuline remained the largest product at €1,135.4m (52.1% in North America), helped by continued generic lanreotide shortages; Iqirvo (€184.0m vs €21.9m) and Bylvay (€180.0m, +32.5%) drove Rare Disease.
- R&D expenses €754.0m, 20.5% of sales; the model leans on external innovation: ImCheck Therapeutics acquired in December 2025 (€350m upfront plus milestones), an ex-China licence for the SIM0613 ADC, and seven pre-clinical assets added since January 2024.
- Free cash flow €1,000.6m (+29.2%); net cash €559.9m at year end; €3.2bn of firepower for R&D pipeline expansion; a €500m 3.875% bond due 2032 and a €1,500m revolving credit facility were put in place in 2025.
- Impairments of €257.6m after tax, mainly Tazverik (lower expected peak sales) and fidrisertib (failed pivotal Phase II in FOP); Tazverik was withdrawn from all markets in March 2026 after safety signals in SYMPHONY-1.
- 2026 guidance: total sales growth greater than 13.0% at constant currency and core operating margin greater than 35.0%; Ipsen is "highly confident" of beating its 2023-2027 targets (average sales growth of at least 7% a year, 2027 core operating margin of at least 32%).
- Main risks rated High: licensing and acquisition integration, partnerships, competition (a few products make up most sales, Somatuline generics), market access and pricing, IT and cyberattacks, geographical footprint (including US tariffs and price regulation), R&D failure.
- Governance: Marc de Garidel chairs the Board, David Loew is CEO since July 2020; the group is family controlled, with Highrock and Beech Tree each holding 26.03% of the share capital at 31 December 2025.

### [Ipsen H1 2026 Results (press release)](https://www.ipsen.com/wp-content/uploads/2026/07/Ipsen-PR_HY-2026_30072026.pdf)

Interim report · 2026-07-30

- H1 2026 total sales €2,190.2m, +20.4% reported and +23.5% at constant exchange rates; the portfolio beyond Somatuline grew 24.8%.
- Core operating income €844.9m (+28.8%), core operating margin 38.6% (+2.5 points); IFRS net profit €402.6m (+20.0%); free cash flow €651.7m (+34.9%); net cash €1,004.9m at 30 June.
- Oncology €1,451.5m (+15.6% CER): Somatuline €686.3m (+21.0%) on generic lanreotide challenges, Cabometyx €350.5m (+18.8%), Decapeptyl €284.3m, Onivyde €108.0m, first Ojemda sales €14.5m.
- Rare Disease €304.7m (+108.0% CER): Iqirvo €173.2m (+209.7%), Bylvay €120.1m (+44.8%); Neuroscience €434.0m (+16.6%), with Dysport aesthetics €256.8m and therapeutics €170.2m.
- FY2026 guidance upgraded: sales growth greater than 20.0% at CER (was greater than 13.0%), core operating margin greater than 37.0% (was greater than 35.0%), including the dilution from the Memo and Kartos acquisitions.
- Pipeline: positive Phase III results for Dysport in both episodic and chronic migraine (BEOND) and for Iqirvo in PBC (ELSPIRE, 85% ALP normalization vs 23% on placebo); Bylvay's BOLD Phase III in biliary atresia failed.
- External innovation: agreement to acquire Kartos Therapeutics (navtemadlin, Phase III in myelofibrosis) for $450m upfront plus up to $1.3bn in milestones; Memo Therapeutics AG (potravitug, BK polyomavirus in kidney transplants) acquired for €200m upfront.
- North America sales €795.4m (+34.0% CER), Europe €824.1m (+14.2%), Rest of World €570.7m (+24.2%).

### [Ipsen H1 2026 Results Conference Call (transcript)](https://www.roic.ai/quote/IPSEY/transcripts/2026-year/2-quarter)

Executive talk · David Loew, Chief Executive Officer · 2026-07-30

- Loew: H1 2026 sales growth of 23.5% at CER and a 38.6% core operating margin, with "three positive Phase III readouts and three late-stage trials underway".
- CFO Aymeric Le Chatelier: after the Kartos and Memo deals Ipsen keeps "more than EUR 2 billion of pro forma firepower" at 2x EBITDA; Somatuline generics now expected more in Q4 than Q3, with a better US pricing environment.
- 2027: sales still expected to grow despite Somatuline generics, but margin "will be impacted" by the acquisitions' R&D and launch preparation for Dysport in migraine.
- Dysport migraine: launch expected in H2 2027 pending approvals; therapeutic toxin market about EUR 4 billion, chronic migraine around 40% of it; Ipsen plans DTC advertising and a larger field force.
- Iqirvo peak sales estimate in PBC raised to EUR 1 billion; about 30,000 US patients above 1.67x ULN ALP plus 20,000 in the ELSPIRE population.
- Business development focus stays on oncology, hematology and rare disease; neuroscience growth relies on corabotase, being developed in three therapeutic indications.
- Onivyde: a competitor (DARA) is expected to enter second line around September, a short-term dip for Onivyde.

### [Ipsen Full Year 2025 Results Conference Call (transcript)](https://www.roic.ai/quote/IPSEY/transcripts/2025-year/4-quarter)

Executive talk · David Loew, Chief Executive Officer · 2026-02-12

- Loew: 2025 sales grew 10.9% at CER, the portfolio excluding Somatuline 14.2%; core operating margin 35.2%.
- 2026 guidance: sales growth above 13% at CER and margin above 35%, assuming limited generic lanreotide supply with a potential entrant only in H2 2026.
- CFO Le Chatelier: EUR 3.2 billion of firepower at a 2x net debt/EBITDA ceiling, plus about EUR 1 billion of free cash flow a year; late-stage oncology deals are a priority.
- Iqirvo: guidance "above EUR 500 million" peak sales, Ocaliva switches "mostly done"; orphan drug protection "until '31"; PSC (Phase III elafibranor at 120 mg) seen as about the same opportunity as PBC, with 40,000 prevalent patients.
- Somatuline: generic lanreotide is "very difficult" to produce; Ipsen expects growth in 2026 from regained volume and pricing upside, with a US price increase taken at the start of the year.
- IPN10200: an ICC arbitral tribunal ruled for Ipsen against Galderma in January 2026, confirming Ipsen's full rights to its aesthetic toxin programs; options for the asset under review.
- Dysport expected to grow high single digit in both aesthetics and therapeutics in 2026.

## Questions about Ipsen

### What does Ipsen do?

Ipsen is a global biopharmaceutical company focused on Specialty Care in Oncology, Rare Disease and Neuroscience. Its medicines include Somatuline, Cabometyx, Decapeptyl, Dysport, Iqirvo and Bylvay.

### What is Ipsen's revenue?

FY2025 total sales were €3,675.9m, up 10.9% at constant exchange rates. H1 2026 sales were €2,190.2m, and FY2026 guidance is sales growth greater than 20.0% at CER.

### How many employees does Ipsen have?

Ipsen had 5,535 employees in 42 countries in 2025.

### What is Ipsen's strategy?

Ipsen grows its Specialty Care portfolio through its global commercial presence while building its pipeline mainly through external innovation, with recent deals such as ImCheck, Memo and Kartos.

### Who leads Ipsen?

David Loew has been CEO since July 2020, and Marc de Garidel chairs the Board. Aymeric Le Chatelier is CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
